Fig. 4.

Tumor growth inhibition with MTD and metronomic paclitaxel formulations. MDA-MB-231 cells were implanted in the nude mice on the zeroth day, and the treatment was started on the 11th day when the tumor volume reached 150–200 mm³. The regimen of MTD treatment was administering Taxol or SSL-PTX (15 mg/kg) on the 11th, 15th, 19th, and 23 rd day, respectively. For metronomic treatment, Taxol or SSL-PTX (6 mg/kg) was administered from the 11th to 15th days and from the 22nd to 26th days, respectively. On the 32nd day, one of five mice in the control group began to seem moribund; thus, all nude mice were sacrificed, and the tumor was harvested. Data (change ratio for tumor volume (%)) are presented as the mean ± SD per group measured at indicated days after treatment (n = 5). **, p < 0.01, vs control treatment group at the 32nd day; ††, p < 0.01, vs metronomic Taxol treatment group at the 32nd day